Verification and diagnostic evaluation of the RealStar® Middle East respiratory syndrome coronavirus (N gene) reverse transcription-PCR kit 1.0

Future Microbiol. 2019 Jul;14(11):941-948. doi: 10.2217/fmb-2019-0067. Epub 2019 Jul 4.

Abstract

Aim: We report the diagnostic evaluation of a confirmatory reverse transcription-PCR (RT-PCR) kit targeting the Middle East respiratory syndrome coronavirus (MERS-CoV) N gene. Material & methods: 33 patient samples from two collections sites in Riyadh, Saudi Arabia, which were pre-characterized via real-time RT-PCR targeting MERS-CoV orf1a and upE, and were tested using the MERS-CoV N gene, as a confirmatory assay. This diagnostic procedure follows a two-step diagnostics scheme, recommended by the WHO. Results: 18/33 samples tested positive, 11/33 tested negative for MERS-CoV RNA and 2/33 showed uncertain results. Conclusion: The results suggest, that the RealStar® MERS-CoV (N gene) RT-PCR kit 1.0 can be considered a suitable and reliable confirmatory assay in combination with the RealStar MERS-CoV RT-PCR kit 1.0 according to the diagnostic scheme recommended by WHO.

Keywords: MERS-CoV; WHO diagnostic scheme; diagnostics; emerging diseases; molecular diagnostics; preparedness; real-time RT-PCR.

Publication types

  • Validation Study

MeSH terms

  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / virology*
  • Coronavirus Nucleocapsid Proteins
  • Humans
  • Middle East Respiratory Syndrome Coronavirus / genetics*
  • Middle East Respiratory Syndrome Coronavirus / isolation & purification
  • Molecular Diagnostic Techniques / methods*
  • Nucleocapsid Proteins / genetics
  • RNA, Viral / genetics
  • Real-Time Polymerase Chain Reaction*
  • Saudi Arabia
  • Sensitivity and Specificity

Substances

  • Coronavirus Nucleocapsid Proteins
  • Nucleocapsid Proteins
  • RNA, Viral